Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children

Coronavirus disease (COVID-19) is an emergency pandemic with a high mortality rate worldwide. One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist used to suppress th...

Descripción completa

Detalles Bibliográficos
Autores principales: Alolayan, Abdulaziz, Aldamegh, Abdullah S., Alkhayrat, Azzah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991479/
https://www.ncbi.nlm.nih.gov/pubmed/36895203
http://dx.doi.org/10.1155/2023/8530060
Descripción
Sumario:Coronavirus disease (COVID-19) is an emergency pandemic with a high mortality rate worldwide. One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist used to suppress the exaggerated inflammatory response in such conditions, and it is potentially lifesaving in a cytokine storm. We present the case of a patient with critical COVID-19 associated with multisystem inflammatory syndrome in children (MIS-C) successfully treated with anakinra intravenous (IV) infusion.

Ejemplares similares